Clinical Sequencing Evidence-Generating Research (CSER)

Clinical Sequencing Evidence-Generating Research (CSER)
Name	Clinical Sequencing Evidence-Generating Research
Abbr	CSER
Established	2010s
Focus	Genomic medicine, clinical sequencing
Funder	National Human Genome Research Institute

Clinical Sequencing Evidence-Generating Research (CSER) is a coordinated research initiative focused on generating evidence about the clinical use of genomic sequencing technologies in healthcare settings. Launched to evaluate clinical utility, implementation, and outcomes, the program engaged multidisciplinary teams to study diagnostic yield, clinical decision-making, and patient-centered outcomes across diverse populations. CSER activities intersected with policy debates, regulatory frameworks, and translational efforts to move sequencing from research into clinical practice.

Overview

CSER originated from funding by the National Human Genome Research Institute and collaborated with institutions such as National Institutes of Health, Mayo Clinic, Broad Institute, Stanford University, Massachusetts General Hospital, Johns Hopkins Hospital, University of California, San Francisco, Children's Hospital of Philadelphia, Vanderbilt University Medical Center, University of Washington, Columbia University, University of Pennsylvania, University of Chicago, Cleveland Clinic, Emory University, University of North Carolina at Chapel Hill, Duke University, University of Michigan, University of Pittsburgh, Oregon Health & Science University, Geisinger Health System, Yale University, Harvard Medical School, Oxford University, Cambridge University, Imperial College London, King's College London, University of Toronto, McGill University, University of British Columbia, Karolinska Institutet, University of Melbourne, Monash University, University of Sydney, National Institute for Health and Care Research, Wellcome Trust, Bill & Melinda Gates Foundation, Robert Wood Johnson Foundation, American College of Medical Genetics and Genomics, European Society of Human Genetics, American Society of Human Genetics, Clinical Laboratory Improvement Amendments, Food and Drug Administration, Centers for Medicare & Medicaid Services, Office for Human Research Protections, World Health Organization, Pan American Health Organization, European Commission .

Research Objectives and Study Design

CSER projects pursued objectives including evaluation of diagnostic yield, genotype–phenotype correlations, and comparative effectiveness. Participating centers designed cohort studies, randomized trials, and implementation science projects involving populations from tertiary referral centers to community clinics affiliated with Kaiser Permanente, Veterans Health Administration, Mount Sinai Health System, Intermountain Healthcare, Providence Health & Services, Partners HealthCare, Sutter Health, Baylor College of Medicine, Texas Children's Hospital, St. Jude Children's Research Hospital, Seattle Children's Hospital, Ann & Robert H. Lurie Children's Hospital of Chicago, Boston Children's Hospital, Royal Children's Hospital, Melbourne, Great Ormond Street Hospital, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust. Study designs incorporated prospective enrollment, family-based analyses, population screening pilots, and health-services outcomes assessed with instruments used by Agency for Healthcare Research and Quality, National Quality Forum, and Patient-Centered Outcomes Research Institute.

Clinical and Laboratory Methods

CSER standardized sequencing methods across clinical laboratories accredited under Clinical Laboratory Improvement Amendments and often seeking guidance from the American College of Medical Genetics and Genomics. Methods included exome sequencing, genome sequencing, targeted panels, trio analysis, and orthogonal confirmation by Sanger sequencing or multiplex ligation-dependent probe amplification used in labs linked to Illumina, Inc., Thermo Fisher Scientific, Agilent Technologies, Roche, Oxford Nanopore Technologies, PacBio platforms. Bioinformatics pipelines referenced standards from Global Alliance for Genomics and Health and interoperability efforts aligned with HL7 and Fast Healthcare Interoperability Resources. Variant interpretation used criteria from ACMG guidelines and leveraged databases such as ClinVar, gnomAD, dbSNP, COSMIC, Human Gene Mutation Database.

Ethical, Legal, and Social Implications

CSER emphasized informed consent models, return of results policies, and concerns about privacy and discrimination invoking statutes like the Genetic Information Nondiscrimination Act and oversight by Institutional Review Boards. Projects navigated issues addressed by Belmont Report principles and considered data sharing frameworks promoted by National Institutes of Health policy and infrastructures such as dbGaP, European Genome-phenome Archive, All of Us Research Program, UK Biobank, 100,000 Genomes Project. Community engagement involved partnerships with organizations such as Association of American Indian Physicians, National Urban League, UNICEF, American Civil Liberties Union, Cystic Fibrosis Foundation, Alzheimer's Association, Susan G. Komen Foundation.

Outcomes, Evidence Integration, and Impact

CSER produced evidence on diagnostic rates for rare diseases, pharmacogenomics actionability, cascade testing, and psychosocial outcomes reported in journals like The New England Journal of Medicine, Nature Medicine, The Lancet, JAMA, Genetics in Medicine, American Journal of Human Genetics, BMJ, PLOS Medicine, Science Translational Medicine. Findings informed practice guidelines by American College of Medical Genetics and Genomics, reimbursement decisions influenced by Centers for Medicare & Medicaid Services, and policy discussions in forums such as National Academies of Sciences, Engineering, and Medicine and World Health Assembly sessions. Integration into electronic health records engaged vendors and standards bodies including Epic Systems Corporation, Cerner Corporation, Intermountain Healthcare, and Health Level Seven International.

Stakeholders and Collaboration

CSER convened stakeholders across academia, industry, patient advocacy groups, regulatory agencies, and payers including Blue Cross Blue Shield Association, UnitedHealth Group, Aetna, Cigna, Anthem, Inc., Centers for Disease Control and Prevention, National Cancer Institute, National Heart, Lung, and Blood Institute, European Medicines Agency, Pharmaceutical Research and Manufacturers of America, Biotechnology Innovation Organization, American Medical Association, American Nurses Association, Society for Academic Emergency Medicine.

Challenges and Future Directions

Challenges identified by CSER included disparities in genomic reference databases exemplified by underrepresentation of populations from regions such as Nigeria, India, Brazil, Mexico, China, Indonesia, Pakistan, Bangladesh, Ethiopia, Kenya, South Africa, Egypt, Turkey, Russia, Ukraine, Poland, Italy, Spain, France, Germany, and the need for scalable diagnostic workflows, cost-effectiveness evidence for payers like Centers for Medicare & Medicaid Services and Blue Cross Blue Shield Association, and interoperability across systems such as Epic Systems Corporation and Cerner Corporation. Future directions include integration with learning health systems exemplified by All of Us Research Program and expansion of implementation studies in health systems like Kaiser Permanente and Geisinger Health System, engagement with global initiatives such as the 100,000 Genomes Project and Global Alliance for Genomics and Health, and translational pathways involving collaboration with industry partners like Illumina, Inc. and Roche to accelerate equitable clinical adoption.

Category:Genomic medicine